Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories
Activist investor Elliott Investment Management has acquired a significant stake in Bio-Rad Laboratories, Inc. and plans to advocate for improved share performance. Bio-Rad's substantial investment in Sartorius, valued at approximately $5 billion, is a key focus for Elliott, representing a significant portion of Bio-Rad's market capitalization. Despite a recent decline in Bio-Rad's share price and slight earnings miss, the company's turnaround potential and the value of its Sartorius stake could make it an attractive acquisition target.
How Investors Are Reacting To Bio-Rad Laboratories (BIO) As RBC Sees Margin Upside Under New Leadership
RBC Capital has restarted coverage of Bio-Rad Laboratories (BIO) with an Outperform rating, anticipating improved margins under new leadership and a sales recovery by 2027. This positive outlook is supported by recent share repurchases and strategic platform rollouts, reinforcing the importance of margin repair as a key near-term catalyst. However, investors should remain aware of potential risks from prolonged weakness in research and clinical demand.
Bio-Rad Laboratories, Inc. Class B Trade Ideas — LS:862449
This article compiles various trade ideas and analyses for Bio-Rad Laboratories, Inc. (LS:862449, NYSE:BIO) from different users on TradingView. It includes both long and short positions based on technical indicators like RSI, EMA, and pivot points, as well as fundamental analysis and analyst ratings. The ideas reflect different strategies and market outlooks for the company's stock.
Number of shareholders of Bio-Rad Laboratories, Inc. Class B – LS:862449
This article provides information about the number of shareholders for Bio-Rad Laboratories, Inc. Class B (LS:862449). It appears to be a page from TradingView, presenting financial data and market information for the company. The core content seems to be a placeholder for shareholder data, alongside various navigation and informational links.
About Us | Oil & Gas Journal - Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO) Stock Quote
This article provides detailed stock information for Bio-Rad Laboratories, Inc. (NYSE:BIO), including its current price, trading volume, and performance metrics. It also lists recent news headlines related to the company, focusing on earnings reports, investor conferences, and other financial updates. The page also serves as an "About Us" section for Oil & Gas Journal, outlining its mission to cover the oil and gas industry.
(BIO) Movement as an Input in Quant Signal Sets
This article provides an analysis of Bio-rad Laboratories Inc. Class A (NYSE: BIO), indicating weak near and mid-term sentiment but a positive long-term outlook. It presents institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report highlights AI-generated signals for support and resistance levels across different time horizons.
A Look At Bio-Rad (BIO) Valuation After Q1 2026 Net Loss And Outlook Cut
Bio-Rad Laboratories (BIO) experienced a Q1 2026 net loss of US$527.1 million and reduced revenue outlook, yet Simply Wall St's analysis suggests the stock is 19.9% undervalued with a fair value of $321.25. This valuation is based on expected growth in molecular diagnostics and precision medicine, driven by new product launches and acquisitions, despite current challenges like weaker bioprocessing demand and gross margin pressures. Investors are advised to consider both the narrative of undervaluation and the cautious P/E ratio, which currently stands at 40.8x compared to a fair ratio of 15.3x.
Bio-Rad Laboratories Inc. Class A (BIO) Stock Price | Live Quotes & Charts | NYSE
This page provides live quotes and charts for Bio-Rad Laboratories Inc. Class A (BIO) stock on the NYSE, showing a current price of $254.32, down $3.00 (-1.17%). It notes that there are no analyst ratings or earnings information currently available for the company. The page also includes an advertisement for options trading skills and a form to sign up for daily trade alerts.
Bio-Rad Laboratories, Inc. Class A Common Stock (NY: BIO
This article provides a list of recent news and press releases concerning Bio-Rad Laboratories, Inc. (NYSE: BIO), including financial results disclosures, management changes, and conference participation announcements. It covers events from early 2023 through mid-2024, highlighting the company's continuous engagement with investors and the public. The stock's performance on the day of the article's crawl is also noted.
Bio Rad Laboratories (BIO) EPS Loss Revives Concerns Over Volatile Profit Narratives
Bio-Rad Laboratories (BIO) reported a Q1 2026 basic EPS loss of US$19.55, despite an increase in quarterly revenue. This volatility in earnings, with net income swinging from a US$720 million gain to a US$527 million loss, raises concerns about the company's profit stability. While trailing twelve-month figures show a return to profit, modest growth forecasts and a 41x P/E ratio suggest a cautious outlook for investors.
Bio-Rad Weighs 2026 Outlook As Middle East Headwinds Meet Stilla Hopes
Bio-Rad Laboratories (NYSE:BIO) has issued a cautious revenue outlook for 2026, citing a material impact from geopolitical disruptions in the Middle East, which led to a quarterly net loss of US$527.1 million despite sales being in line with guidance. The company plans to counter these headwinds through the Stilla acquisition, expected to be accretive within the year, and by focusing on business efficiency measures and high-margin areas like ddPCR technology and process chromatography. While analysts note the stock trades below its fair value, investors are advised to monitor the integration of Stilla, cost management, and the consistency of future earnings.
Bio-Rad Laboratories (BIO) Releases Q1 2026 Earnings: Revenue Up Slightly, EPS Deeply Negative on Large GAAP Loss
Bio-Rad Laboratories (BIO) reported Q1 2026 revenue of $592.1 million, a 1.1% increase year-over-year, and a strong operating profit increase. Despite improved operating performance and cash flow, the company posted a deeply negative diluted EPS of -19.55 due to a large GAAP net loss of $527.1 million, missing analyst estimates for both revenue and EPS.
Bio-Rad Laboratories (BIO) Releases Q1 2026 Earnings: Revenue Up Slightly, EPS Deeply Negative on Large GAAP Loss
Bio-Rad Laboratories (BIO) reported Q1 2026 revenue of $592.1 million, a 1.1% increase year-over-year, which was slightly below consensus estimates. Despite improving operating performance and stronger operating cash flow, the company recorded a large GAAP net loss of $527.1 million, resulting in a deeply negative diluted EPS of -19.55, significantly missing analyst estimates. The report also highlights hedge fund activity in BIO stock and recent government contracts awarded to the company.
Transcript: Bio-Rad Laboratories Q1 2026 Earnings Conference Call
Bio-Rad Laboratories reported a 1.1% increase in net sales for Q1 2026, but a 4.2% decrease on a currency-neutral basis, primarily due to geopolitical conflicts in the Middle East and challenges in academic funding. The company adjusted its full-year 2026 guidance to between -3% and +0.5% currency-neutral revenue growth. Despite the headwinds, Bio-Rad is focusing on innovation, particularly in its digital PCR product line which saw 24% instrument revenue growth, and aims for mid-teens operating margins in the near term through operational efficiencies and disciplined M&A.
Bio-Rad (NYSE: BIO) CFO nets more shares after RSU vesting and tax withholding
Bio-Rad Laboratories' EVP and CFO Roop Kalyan Lakkaraju acquired 1,078 shares of Class A common stock through RSU vesting on April 24, 2026. To cover tax obligations, 420 shares were disposed of at $287.84 per share, resulting in a net increase in direct holdings. After these transactions, Lakkaraju directly holds 2,563.895 Class A shares and has 2,156 restricted stock units remaining.
Bio-Rad (BIO) EVP Courtney Enloe gains shares via RSU vesting, withholds for taxes
Bio-Rad Laboratories' EVP and General Counsel, Courtney C. Enloe, acquired 186 shares of Class A common stock through the vesting of restricted stock units (RSUs) on April 24, 2026. She subsequently had 77 shares withheld to cover tax obligations. After these transactions, her direct holdings of Class A shares increased to 826.777, and her remaining RSU balance from an original 744-unit grant is 372 units.
Bio-Rad Laboratories, Inc. Amends 2017 Incentive Award Plan and Updates Entity Information in April 2026 8-K Filing
Bio-Rad Laboratories, Inc. announced key developments from its 2026 Annual Meeting. Shareholders approved significant amendments to the 2017 Incentive Award Plan, including an increase in the share reserve and an extension of the plan's expiration date. Additionally, all nominated directors were elected, KPMG LLP was ratified as the independent auditor, and a shareholder proposal concerning the company's dual-class capital structure was not approved, maintaining the existing governance.
Shareholders of Bio-Rad (NYSE: BIO) approve 2017 incentive plan changes
Bio-Rad Laboratories' stockholders approved an amended 2017 Incentive Award Plan at their April 21, 2026 annual meeting, increasing reserved shares by 335,000 and extending the plan to March 18, 2036. All nominated directors were elected, KPMG LLP was ratified as auditor, and executive compensation received majority support in an advisory vote. A proposal regarding the company's dual-class capital structure did not pass.
Bio-Rad (NYSE: BIO) director exercises 407 RSUs and gains 369 new units
Jeffrey L. Edwards, a director at Bio-Rad Laboratories (NYSE: BIO), exercised 407 restricted stock units (RSUs) into common shares and received an additional grant of 369 new RSUs. This transaction increased his direct holdings of Bio-Rad Class A common stock to 715 shares, while the 407 previously held RSUs were fully converted. The newly granted RSUs will vest 100% on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders.
Bio-Rad (BIO) director Arnold Pinkston gains shares, receives new RSU grant
Bio-Rad Laboratories, Inc. director Arnold A. Pinkston reported routine equity compensation, acquiring 407 shares of Class A common stock from vested restricted stock units (RSUs). After this transaction, his direct common stock holdings total 715 shares. Additionally, Pinkston received a new grant of 369 restricted stock units, which will vest 100% on the earlier of one year from the grant date or the company's next annual meeting of stockholders.
Bio-Rad (NYSE: BIO) director exercises 407 RSUs and receives 369-unit grant
Bio-Rad Laboratories director Melinda Litherland engaged in routine equity compensation activities, exercising 407 restricted stock units (RSUs) into common stock, bringing her total direct holdings to 715 shares. Concurrently, she received a new grant of 369 RSUs, which will vest 100% on the earlier of the first anniversary of the grant date or the company's next annual meeting of stockholders. These transactions, reported on a Form 4 SEC filing, are considered neutral in impact and sentiment, aligning her compensation with future company performance.
Greg K. Hinckley adds Bio-Rad (BIO) shares through RSU vesting and grant
Bio-Rad Laboratories director Greg K. Hinckley increased his direct equity stake through the vesting of 407 restricted stock units (RSUs) into common stock and a new grant of 369 RSUs on April 21, 2026. Following these transactions, Hinckley directly holds 1,215 shares of Class A common stock. The newly granted RSUs will vest 100% on the earlier of their first anniversary or the company’s next annual meeting of stockholders.
Why (BIO) Price Action Is Critical for Tactical Trading
This article analyzes Bio-Rad Laboratories Inc. Class A (NYSE: BIO) with a focus on its price action for tactical trading, driven by predictive AI. It highlights strong sentiment across all horizons, identifies a mid-channel oscillation pattern, and notes an exceptional risk-reward short setup. The analysis provides specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels.
Understanding Momentum Shifts in (BIO)
This article analyzes Bio-rad Laboratories Inc. Class A (NYSE: BIO), indicating a neutral near-term sentiment amidst mid and long-term strength. It highlights a significant 41.8:1 risk-reward setup targeting a 12.0% gain versus 0.3% risk. The analysis also provides three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
Artisan Mid Cap Value Fund Sold Bio-Rad Laboratories (BIO) in Q4
Artisan Mid Cap Value Fund divested its position in Bio-Rad Laboratories (NYSE: BIO) during Q4 2025, according to its investor letter. While acknowledging Bio-Rad's business, the fund expressed concern over the CEO's capital allocation strategy, specifically regarding large M&A. The proceeds from the sale were used to purchase Revvity.
Avoiding Lag: Real-Time Signals in (BIO) Movement
This article from Stock Traders Daily discusses real-time trading signals for Bio-rad Laboratories Inc. Class A (NYSE: BIO). It highlights the stock's strong near-term sentiment while noting potential breakdowns and elevated downside risk. The analysis includes three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for different horizons.
Discipline and Rules-Based Execution in BIO Response
This article analyzes Bio-Rad Laboratories Inc. (NYSE: BIO) with AI-generated trading strategies. It highlights weak near-term sentiment but strong long-term prospects, identifying key support and resistance levels. The analysis provides specific entry and exit points for position trading, momentum breakout, and risk hedging strategies, emphasizing disciplined, rules-based execution.
Behavioral Patterns of BIO and Institutional Flows
This article analyzes Bio-rad Laboratories Inc. Class A (NYSE: BIO) with AI-generated signals and strategies. It identifies a near-term strong sentiment, mid-term neutrality, and long-term positive bias, noting a current breakdown with elevated downside risk. The report provides specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies.
Is It Time To Reconsider Bio-Rad Laboratories (BIO) After Its Prolonged Share Price Slump
Bio-Rad Laboratories (BIO) has experienced a significant share price slump over the past five years, prompting a re-evaluation of its valuation. Despite the historical decline, a Discounted Cash Flow (DCF) analysis suggests the stock is currently undervalued by 33.4%, with an intrinsic value of about $418.03 per share compared to its current trading price of around $278.44. Additionally, its P/E ratio of 9.89x is considerably lower than the Life Sciences industry average, further indicating it may be trading below its fair value.
Equipment and Facilities
Lake Forest College's Biochemistry and Molecular Biology department provides a comprehensive list of its available equipment and facilities. The resources range from nucleic acid preparation and analysis tools like gradient thermal cyclers and quantitative PCR instruments to cell preparation, tissue culture, and analysis facilities including fluorescent microscopy and mammalian cell culturing hoods. The department also boasts various advanced instruments such as NMR, UV/Vis spectrophotometers, X-ray equipment, chromatography and mass spectroscopy systems, and fluorimetry and photolysis apparatus, alongside general miscellaneous lab equipment.
Bio-Rad Laboratories, Inc. (BIO) achieves modest revenue growth and robust free cash flow growth
Bio-Rad Laboratories (BIO) reported modest revenue growth of 2.1% but demonstrated strong free cash flow growth of 30.7%. Despite this, the company's valuation appears stretched with a Price-to-Earnings (P/E) ratio of 55.4 and an Enterprise Value to Sales (EV/Sales) of 4.7. Investors should consider the potential for growth to decelerate and how that might impact future returns, especially given the current valuation.
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain
Bio-Rad's revenue growth recovery is facing uncertainty, pushed back by its 2026 guidance. The company, a leader in life sciences research and clinical diagnostics, relies on a "razor-and-blade" model with consumables accounting for about 70% of sales. Despite a soft market, previous reports indicated the company was on track to meet full-year targets.
BIO-RAD LABORATORIES, INC. SEC 10-K Report
Bio-Rad Laboratories, Inc. has released its annual Form 10-K report for the fiscal year ended December 31, 2025, detailing financial performance, business operations, and strategic initiatives. The company reported net sales of $2,583.2 million, a significant increase in net income to $759.9 million, and continued challenges in the biopharma market. Strategic initiatives include the acquisition of Stilla Technologies and maintaining a strong liquidity position, while significant risks include market competition, supply chain disruptions, and global economic conditions.
Earnings Flash (BIO) Bio-Rad Laboratories, Inc. Reports Q4 Revenue $693.2M, vs. FactSet Est of $688.8M
Bio-Rad Laboratories, Inc. (BIO) reported its Q4 revenue at $693.2 million, surpassing the FactSet estimate of $688.8 million. This earnings flash highlights the company's financial performance, specifically its revenue outperforming analyst expectations for the fourth quarter.
Mawer Investment Management Ltd. Reduces Holdings in Bio-Rad Laboratories, Inc. $BIO
Mawer Investment Management Ltd. significantly reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 8.9% in Q3, selling 23,640 shares. Despite this reduction, other institutional investors, such as First Eagle Investment Management LLC, increased their holdings, and institutional investors collectively own 65.24% of the company's stock. Analyst ratings for Bio-Rad are mixed, with a consensus "Hold" rating and an average price target of $358.50, although some analysts have upgraded their ratings or price targets.
Trading Systems Reacting to (BIO) Volatility
This article analyzes Bio-rad Laboratories Inc. Class A (NYSE: BIO), noting weak near and mid-term sentiment despite a long-term positive outlook. It highlights a mid-channel oscillation pattern and presents an exceptional 42.2:1 risk-reward setup targeting a 12.2% gain. The piece outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors.
What Bio-Rad Laboratories (BIO)'s AI-Driven Protein Assay Upgrades Mean For Shareholders
Bio-Rad Laboratories has enhanced its protein assay portfolio with more sensitive kits and integrated AI, IoT, and blockchain to improve accuracy and efficiency, broadening their application in research and diagnostics. While these upgrades align with Bio-Rad's strategy as a core tools provider, they are not yet considered a major catalyst for the company's investment narrative, which currently focuses on margin improvement, management execution, and share buybacks amidst weak stock performance and modest revenue growth. The article also notes that Bio-Rad’s shares might still be overvalued, despite recent corrections.
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Rating of "Hold" from Analysts
Bio-Rad Laboratories (NYSE:BIO) has received an average "Hold" rating from six analysts, with an average 12-month target price of $358.50. The company's stock currently trades around $295.92 and has a market capitalization of approximately $7.98 billion. Recent financial results showed an EPS of $2.26, missing estimates, and an EVP recently sold 700 shares.
Is Bio-Rad Laboratories (BIO) Starting To Look Attractive After Prolonged Share Price Weakness?
Bio-Rad Laboratories (BIO) has experienced significant share price weakness over recent years but is currently scoring as undervalued based on Simply Wall St's checklist-based valuation framework. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 22.2%, and its Price/Sales ratio also indicates a modest discount compared to its "Fair Ratio." The article encourages investors to use "Narratives" on Simply Wall St's platform to personalize their valuation based on individual assumptions.
SG Americas Securities LLC Buys 5,600 Shares of Bio-Rad Laboratories, Inc. $BIO
SG Americas Securities LLC significantly increased its stake in Bio-Rad Laboratories (NYSE:BIO) by 688% in the third quarter, acquiring an additional 5,600 shares, bringing its total to 6,414 shares valued at $1.798 million. Despite this institutional buying, an EVP insider sold 700 shares, reducing his holding by nearly 58%. Bio-Rad Laboratories reported Q3 EPS of $2.26, slightly missing consensus estimates, and currently holds a "Hold" consensus rating from analysts with a target price of $358.50.
(BIO) and the Role of Price-Sensitive Allocations
This article provides a detailed analysis of Bio-rad Laboratories Inc. Class A (NYSE: BIO), highlighting a strong near and mid-term sentiment and an exceptional risk-reward short setup. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and AI-generated signals for support and resistance levels. The analysis suggests a potential 13.6% downside versus a 0.3% risk based on current signals.
Responsive Playbooks and the BIO Inflection
This article provides an AI-driven analysis for Bio-rad Laboratories Inc. Class A (NYSE: BIO), highlighting a neutral near-term sentiment and a mid-channel oscillation pattern. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis and an exceptional risk-reward setup targeting a 16.4% gain.
Liquidity Mapping Around (BIO) Price Events
The article provides a detailed liquidity mapping analysis for Bio-rad Laboratories Inc. Class A (NYSE: BIO), highlighting weak near and mid-term sentiment but a neutral long-term outlook. It outlines institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and AI-generated signals for potential price movements. The analysis identifies key support and resistance levels and suggests a highly favorable risk-reward setup.
Avoiding Lag: Real-Time Signals in (BIO) Movement
Bio-rad Laboratories Inc. Class A (NYSE: BIO) is showing strong near-term sentiment that could challenge persistent mid and long-term weakness. The article highlights an exceptional 56.8:1 risk-reward short setup targeting a 16.3% downside versus a 0.3% risk. AI models have generated distinct trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Bio-Rad Laboratories (BIO): Assessing Valuation Following Q3 Loss and Share Buyback Completion
Bio-Rad Laboratories (BIO) reported a Q3 net loss and completed a share buyback, leading to an 11.9% share price rebound recently despite long-term underperformance. The company is considered 5.1% undervalued with a fair value of $324, driven by expanded molecular diagnostics platforms and strategic acquisitions. However, this optimism is tempered by persistent instrument demand weakness and margin pressures.
BIO-RAD LABORATORIES Earnings Results: $BIO Reports Quarterly Earnings
BIO-RAD LABORATORIES ($BIO) reported its quarterly earnings on October 29th, with earnings per share of $2.26, surpassing the estimated $1.95. However, the company missed revenue estimates, reporting $653 million against an expectation of $657.81 million. The article also provides details on hedge fund activity, government contracts received by $BIO, and recent analyst ratings and price targets.
Bio-Rad Laboratories (BIO): Evaluating Valuation After Major Oncology Diagnostics Partnership Expansion with Biodesix
Bio-Rad Laboratories and Biodesix are expanding their partnership to develop new in vitro diagnostic assays for oncology, leveraging Bio-Rad's Droplet Digital PCR technology. While the stock has seen a recent surge, its five-year returns remain negative, prompting questions about its current valuation. Analysts present differing fair value assessments, with some suggesting overvaluation while a Discounted Cash Flow model indicates significant undervaluation.
Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays
Biodesix has announced an expanded partnership with Bio-Rad Laboratories to develop and clinically validate in vitro diagnostic (IVD) assays using Bio-Rad’s Droplet Digital™ PCR (ddPCR™) technology. The initial focus is on the ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer, which will help detect ESR1 mutations from ctDNA samples. This collaboration aims to provide sensitive biomarker detection for cancer treatment monitoring and support targeted therapeutic development.
Biodesix Expands Partnership with Bio-Rad for Development of Advanced Cancer Diagnostics Using ddPCR Technology
Biodesix has expanded its partnership with Bio-Rad to develop and validate in vitro diagnostic assays for sensitive genomic marker detection in oncology, utilizing Bio-Rad's Droplet Digital™ PCR technology. The initial focus will be on the ddPLEX ESR1 Mutation Detection Assay, crucial for advanced breast cancer treatment. Once validated, Biodesix will offer the assay through its accredited laboratory and seek CMS reimbursement, expanding its personalized medicine offerings.
Earnings call transcript: Bio-Rad Labs Q2 2025 shows steady growth - Investing.com India
This article from Investing.com India is an earnings call transcript for Bio-Rad Labs' Q2 2025, which indicates steady growth for the company. However, the full article content is replaced by an application error message, preventing the display of the actual transcript details.
